Radboud Annals of Medical Students

RAMS

  • Home
  • News
    • Newsletter archive
  • About
    • RAMS
    • The Board
      • The General Board
        • The General Board (2021-2022)
        • Previous General Boards
      • The Editorial Board
        • The Editorial Board (2021-2022)
        • Previous Editorial Boards
    • The Supervisory Board
    • Reviewers and Editors
    • RAMS Committees
      • Symposium Committee
      • Masterclass Committee
  • Editions
    • 2021-2022
      • Twentieth Edition – September 2021
      • Twentyfirst Edition – December 2021
      • Twenty second Edition – March 2022
    • 2020-2021
      • Sixteenth edition – September 2020
      • Seventeenth edition – December 2020
      • Eighteenth edition – March 2021
      • Nineteenth Edition – June 2021
    • 2019-2020
      • Fourteenth edition – December 2019
      • Fifteenth edition – April 2020
      • Sixteenth edition – September 2020
    • 2018-2019
      • Eleventh Edition – September 2018
      • Twelfth Edition – January 2019
      • Thirteenth edition – May 2019
    • 2017 – 2018
      • Ninth Edition – November 2017
      • Tenth Edition – February 2018
    • 2016-2017
      • Sixth Edition – November 2016
      • Seventh Edition – March 2017
      • Eighth Edition – July 2017
    • 2015-2016
      • Third Edition – November 2015
      • Fourth Edition – March 2016
      • Fifth Edition – June 2016
    • 2014-2015
      • Pilot Edition – June 2014
      • First Edition – January 2015
      • Second Edition – June 2015
  • For Authors
    • Submit your Article
    • Research internship
  • For Supervisors
  • For Reviewers
  • Contact
  • Privacy policy
Je bent hier: Home / News / Pharmacogenetics: Are your genes to blame for your side effects?

Pharmacogenetics: Are your genes to blame for your side effects?

18 april 2021 by Rams

Aster Witvliet, BSc Liberal Arts and Sciences, Science major

Have you ever taken a medication that had a nasty side effect? Or have you taken a medication that appeared to do absolutely nothing to alleviate your health complaint? Not all people respond the same to taking a specific drug; for some people, it might work well, while it might not work at all for others or come with troubling side effects. Your genes might be to blame for the side effects and reduced effectiveness of your medication, as your genes can influence your body’s response to a drug [1]. The field of pharmacogenetics studies this relationship between people’s genes and their response to medications [1]. Research in this field can help personalise treatment, as looking at someone’s genetics can help a physician choose a medication that is likely to be effective and avoid medication that is likely to be ineffective or cause major side effects [1].

One case where looking at the relationship between genetics and medication has already proven beneficial is treatment with the immunosuppressant drug azathioprine. Azathioprine reduces the immune system’s activity, which can be useful in treating patients with an autoimmune disorder where the immune system has started attacking the body [2, 3]. The enzyme thiopurine methyltransferase (TPMT) is involved in the metabolism of azathioprine [2]. Some people have a mutation in their TPMT genes, which causes their TPMT enzymes to work less well, or sometimes even not work at all [2]. Patients with lower or no TPMT enzyme activity have a severely increased risk of bone marrow suppression, a life-threatening side effect of azathioprine [3]. A patient that is found to have deficient TPMT enzymes upon genetic testing can then be prescribed a lower dose of azathioprine or receive an alternative medication to prevent life-threatening side effects [2, 3].

The case of azathioprine and the TPMT enzyme shows the potential power of personalising treatment based on a patients’ genetics. Currently, pharmacogenetics is starting to become a part of clinical practice. In the Netherlands, a general practitioner or specialist can have patients genetically tested for the generation of a so-called DNA-passport by the Erasmus MC [4]. For this DNA-passport, the activities of over 20 enzymes are investigated, and the results can have implications for dozens of medications. However, concerns about the evidence base and healthcare workers’ lack of knowledge on pharmacogenetics remain important roadblocks to wide implementation [5]. In the future, as evidence base for pharmacogenetics strengthens and physicians become more familiar with its potential, you might be saved from serious side effects if your doctor takes a quick glance at your genetics.

References

[1] Drew, L. Pharmacogenetics: The right drug for you. Nature 537, S60–S62 (2016).

[2] Wang, L. & Weinshilboum, R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 25, 1629-38 (2006).

[3] Dewit, O., et al. Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients. Clinical biochemistry 44, 1062-1066 (2011).

[4] Erasmus MC. Farmacogenetica [Internet], cited 2021 03-31. Available from: https://www.erasmusmc.nl/nl-nl/patientenzorg/laboratoriumspecialismen/farmacogenetica

[5] Slob, E., et al. What do we need to transfer pharmacogenetics findings into the clinic? Pharmacogenomics 7, 589-592 (2018).

Categorie: News, Uncategorized

RAMS Newsletter

RAMS complies to the GDPR. By submitting your e-mail address to us you agree with our Privacy Policy.

Social Media


Sponsors & Partners

  • Brian Gardner
  • Lauren Mancke
  • Nathan Rice
  • Nick Croft
  • Rafal Tomal
  • Ron Rennick
© Copyright 2014 RADBOUD ANNALS OF MEDICAL STUDENTS · All Rights Reserved · Powered by PLatform11
Beheer cookie toestemming

Om de beste ervaringen te bieden, gebruiken wij technologieën zoals cookies om informatie over je apparaat op te slaan en/of te raadplegen. Door in te stemmen met deze technologieën kunnen wij gegevens zoals surfgedrag of unieke ID's op deze site verwerken. Als je geen toestemming geeft of uw toestemming intrekt, kan dit een nadelige invloed hebben op bepaalde functies en mogelijkheden.

Functioneel Altijd actief
De technische opslag of toegang is strikt noodzakelijk voor het legitieme doel het gebruik mogelijk te maken van een specifieke dienst waarom de abonnee of gebruiker uitdrukkelijk heeft gevraagd, of met als enig doel de uitvoering van de transmissie van een communicatie over een elektronisch communicatienetwerk.
Voorkeuren
De technische opslag of toegang is noodzakelijk voor het legitieme doel voorkeuren op te slaan die niet door de abonnee of gebruiker zijn aangevraagd.
Statistieken
De technische opslag of toegang die uitsluitend voor statistische doeleinden wordt gebruikt. De technische opslag of toegang die uitsluitend wordt gebruikt voor anonieme statistische doeleinden. Zonder dagvaarding, vrijwillige naleving door uw Internet Service Provider, of aanvullende gegevens van een derde partij, kan informatie die alleen voor dit doel wordt opgeslagen of opgehaald gewoonlijk niet worden gebruikt om je te identificeren.
Marketing
De technische opslag of toegang is nodig om gebruikersprofielen op te stellen voor het verzenden van reclame, of om de gebruiker op een website of over verschillende websites te volgen voor soortgelijke marketingdoeleinden.
Beheer opties Beheer diensten Beheer leveranciers Lees meer over deze doeleinden
Bekijk voorkeuren
{title} {title} {title}